Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 320-329

  Zhang, H ^a   Hylander, B L ^a   Levea, C ^a   Repasky, E A ^a   Straubinger, R M ^b   Adjei, A A ^a   Ma, W W ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

fibroblast growth factor receptor; pancreatic cancer; predictive biomarker; tyrosine kinase inhibitor

Indexed keywords

BETA ACTIN; BIM PROTEIN; CASPASE 3; CYCLIN D1; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN BAD; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; PUMA PROTEIN; SHORT HAIRPIN RNA; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SIZE; CANCER SUSCEPTIBILITY; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANTINEOPLASTIC ACTIVITY; CANCER MODEL; EXPLANT; IN VIVO STUDY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BENZIMIDAZOLES; CARCINOGENESIS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; MEMBRANE PROTEINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLONES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84892933278     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.754     Document Type: Article

References (33)

1. American Cancer Society (2011) American Cancer Society. Cancer Facts & Figures 2012. American Cancer Society: Atlanta 2012 pp 1-68.
2. Baum B, Settleman J, Quinlan MP (2008) Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19: 294-308.
3. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
4. Brooks AN, Kilgour E, Smith PD (2012) Molecular pathways: fibroblast growth factor signalling: a new therapeutic opportunity in cancer. Clin Cancer Res 18: 1855-1862.
5. Chen G, Tian X, Liu Z, Zhou S, Schmidt B, Henne-Bruns D, Bachem M, Kornmann M (2010) Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. Br J Cancer 102: 188-195.
6. Cho K, Ishiwata T, Uchida E, Nakazawa N, Korc M, Naito Z, Tajiri T (2007) Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am J Pathol 170: 1964-1974.
7. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE (2010) Targeting fibroblast growth factor receptors blocks PI3K/AKT signalling, induces apoptosis, and impairs mammary tumour outgrowth and metastasis. Cancer Res 70: 4151-4162.
8. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC (2007) Degradation of Mcl-1 by-TrCP mediates glycogen synthase kinase 3-induced tumour suppression and chemosensitization. Mol Cell Biol 27: 4006-4017.
9. Escaffit F, Estival A, Bertrand C, Vaysse N, Hollande E, Clemente F (2000) FGF-2 isoforms of 18 and 22.5 kDa differentially modulate t-PA and PAI-1 expressions on the pancreatic carcinoma cells AR4-2J: consequences on cell spreading and invasion. Int J Cancer 85: 555-562.
10. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA (2005) The anti-tumour effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3: 22.
11. Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M, Naito Z (2012) Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol 180: 1928-1941.
12. Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
13. Katoh M (2008) Cancer genomics and genetics of FGFR2 (review). Int J Oncol 33: 233-237.
14. Katoh Y, Katoh M (2009) FGFR2-related pathogenesis and FGFR2-targeted therapeutics (review). Int J Mol Med 23: 307-311.
15. Kornmann M, Beger HG, Korc M (1998) Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 17: 169-175.
16. Kuniyasu H, Abbruzzese JL, Cleary KR, Fidler IJ (2001) Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol 19: 681-685.
17. Lee SH (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11: 3633-3641.
18. Liu Z, Neiss N, Zhou S, Henne-Bruns D, Korc M, Bachem M, Kornmann M (2007) Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth. Cancer Res. 67: 2712-2719.
19. Mahadevan D, Von Hoff D.D. (2007) Tumour-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6: 1186-1197.
20. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760.
21. Nomura S, Yoshitomi H, Takano S, Shida T, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Miyazaki M (2008) FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br J Cancer 99: 305-313.
22. Nowak NJ, Gaile D, Conroy JM, McQuaid D, Cowell J, Carter R, Goggins MG, Hruban RH, Maitra A (2005) Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 161: 36-50.
23. Ohta T, Yamamoto M, Numata M, Iseki S, Tsukioka Y, Miyashita T, Kayahara M, Nagakawa T, Miyazaki I, Nishikawa K, Yoshitake Y (1995) Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer 72: 824-831.
24. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J (2009) Consensus report of the National Cancer Institute Clinical Trials planning meeting on pancreas cancer treatment. J Clin Oncol 27: 5660-5669.
25. Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, Grant S (2003) Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22: 6231-6242.
26. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661.
27. Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA (2011) Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10: 2157-2167.
28. Wesche J, Haglund K, Haugsten EM (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437: 199-213.
29. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. Committee of the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
30. Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M (1993) Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53: 5289-5296.
31. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL (1993) Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13: 4513-4522.
32. Yi ES, Yin S, Harclerode DL, Bedoya A, Bikhazi NB, Housley RM, Aukerman SL, Morris CF, Pierce GF, Ulich TR (1994) Keratinocyte growth factor induces pancreatic ductal epithelial proliferation. Am J Pathol 145: 80-85.
33. Zang X-P, Lerner M, Brackett D, Pento JT (2009) Influence of KGF on the progression of pancreatic cancer. Anticancer Res 29: 3417-3420.